CAS 1286739-19-2: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one

FRAX597 is an effector protein that belongs to the group of TNF-α. It has been shown to induce apoptosis in cancer cells by activating the cell death pathways, such as the activation of caspases and autophagy. FRAX597 also has a molecular pathogenesis that is different from other anti-tumour drugs. The mechanism underlying this difference is not fully understood, but it may be due to its ability to inhibit enzymes involved in lipid synthesis (e.g., lipoprotein lipase) and cell proliferation (e.g., cyclin D1).

FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).

FRAX597